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We describe virilization in a newborn female secondary to bilateral congenital juvenile granulosa cell
tumor (JGCT). The patient presented with abdominal mass and ambiguous genitalia at birth, and bilateral
ovarian masses were discovered on further imaging. The patient underwent bilateral salpingo-
oophorectomy in staged procedures, as it became apparent that we could not spare the ovaries. Diag-
nosis of JGCT was confirmed by surgical pathology. She required no adjuvant therapy and has no signs of
recurrence at two-year follow-up.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Virilization and ambiguous genitalia in a newborn female is an
uncommon and complex problem with many possible causes. The
most common cause for virilization in genetically female infants is
congenital adrenal hyperplasia (CAH). Other conditions in the dif-
ferential diagnosis include exposure to maternal androgens or
exogenous hormones.We present a case of virilization secondary to
bilateral congenital juvenile granulosa cell tumor (JGCT) with no
other associated abnormalities.
1. Case report
A 5.2-kilogram 37-week gestation female was born to a 42-year-
old G5P2202 woman by Cesarean section for failure to progress.
Pregnancy was complicated by polyhydramnios and pregnancy-
induced hypertension. Ultrasound at 20 weeks was consistent
with a normal female fetus. APGARs at birth were 8 and 9. On
physical exam, she was noted to have a palpable abdominal mass
and ambiguous genitalia. The mid-abdominal mass was firm, mo-
bile, nontender, and 8e10 cm in diameter. She had clitoromegaly
with normal labia majora without evidence of posterior labialof Medicine, Department of
apolis, IN, 46202, USA.
).
ity of North Dakota, Sanford
akota 38122, USA.
Inc. This is an open access article ufusion. Her urethral and vaginal orifices appeared normal, and she
had a patent anus. Basic metabolic panel was normal. Ultrasound
demonstrated an abdominal mass with a cystic component. MRI
revealed a normal uterus and bilateral cystic masses of the ovaries.
OnMRI, the largermassmeasured 7.4 cm 5.2 cm x 4.8 cm, and the
smaller one measured 4.0 cm  2.5 cm  2.2 cm (Fig. 1).
Diagnostic laparoscopy demonstrated a large mass in the
midline originating from the left ovary, as well as a smaller mass
originating from the right ovary that had undergone torsion. Ex-
amination of the left ovary demonstrated multiple small cysts with
no discernible ovarian tissue distinct from themass. The right ovary
was not ischemic and was detorsed. Surgical exploration was
expedited before return of any laboratory values because of
concern for torsion. With the evidently bilateral nature of the pa-
thology, biopsies were obtained of the larger left mass in hopes that
any normal ovarian tissue would be able to be preserved.
Pathology demonstrated juvenile granulosa cell tumor (JGCT)
with no residual normal ovary tissue. Hormonal studies are listed in
Table 1. On day ten of life, she underwent left salpingo-
oophorectomy and right ovarian biopsy with peritoneal washings.
It was impossible to dissect the left Fallopian tube free from the
mass. Right ovary pathology demonstrated JGCT as well, but peri-
toneal fluid was negative for neoplastic cells. After consultation
with oncology, we elected to continue observationwith surgery at a
later date, to allow the possibility of ovary-sparing surgery.
She was discharged from the hospital at 5 weeks of age. Atnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. MRI demonstrating bilateral ovarian masses. Arrowhead: left ovary. Arrow:
right ovary.
Table 1
Laboratory Results.
Lab Test Initial Result At Follow-up Reference Range
Karyotype 46, XX e normal
17-a-OH progesterone 816 ng/dL e <78 ng/dL
DHEA 756 mg/dL 35 mg/dL 88-356 mg/dL
Testosterone 588 mg/dL <10 mg/dL 20-64 mg/dL
Estradiol 32 pg/mL <20 pg/mL <20e53 pg/mL
LH 0.9 mU/mL e 0.1e3.3 mU/mL
FSH <0.2 mU/mL e 2-15 mU/mL
Inhibin A 77 pg/mL e N/A
Inhibin B 345 pg/mL 195 pg/mL <111 pg/mL
Anti-Mullerian hormone 18 ng/mL 32 ng/mL <4.7 ng/mL
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ovary was smaller at 4.2  1.6  1.7 cm on ultrasound. Her follow-
up labs are shown in Table 1. She was readmitted at 4.5 months
with small bowel obstruction. She required adhesiolysis, and it was
evident that her JGCT had not regressed. Right salpingo-
oophorectomy was performed at this time. Pathology demon-
strated very small fragments of ovary with multiple nodules and
cystic areas of JGCT.
Peritoneal washings were again negative. Therefore, the tumor
had been limited to the bilateral ovaries, corresponding to FIGO
stage Ib, for which no chemotherapy is indicated. By Children's
Oncology Group (COG) staging, it would be stage II.
She was lost to follow-up after discharge for 2 years and seen
again at the age of 2.5 years, fortunately without evidence of
recurrence. Tumor markers were normal with Inhibin B less than
10 pg/mL and AMH less than 0.1 ng/mL, and ultrasound demon-
strated no evidence of recurrent or residual tumor. She will
continue long-term surveillance and will require hormone
replacement therapy.2. Discussion
Juvenile granulosa cell tumors (JGCT) are the most common sex
cord-stromal tumor (SCST) in the pediatric population. Gynecologic
tumors make up less than 5% of pediatric neoplasms, and SCSTs are
rare within this group (10%), with germ cell tumors being far more
common (60e70%). SCST most commonly presents between four
and nine years of age and JGCT are exceedingly rare in infancy
[1e4].
In a 20-year series from Pakistan, the median age of presenta-
tion of JGCT was fourteen years, with only two occurring before one
year of age [5]. Bouffet et al. had similar findings in a comprehen-
sive review in 1997 [1]. Only 25 cases of JGCT in infants less than
one year old have been documented [6,7]. Bilateral ovarian JGCT
occurs in about three percent of cases, but in infants, this tends tobe associated with other congenital abnormalities (Ollier's disease,
Maffucci's syndrome, leprechaunism) [2,8].
Typical presentation of JGCT is abdominal pain and distension,
frequently associated with endocrine manifestations such as iso-
sexual pseudoprecocity or virilization in the pre-menarchal popu-
lation. Occasionally, JGCT may present with peritonitis from torsion
or hemorrhagic shock secondary to tumor rupture. Work-up for
endocrine disturbances and associated genetic abnormalities is
indicated in these patients. Hormone levels should be obtained at
baseline as tumor markers.
Once the diagnosis has been established, resection is the
appropriate management, as these tumors are hormonally active
and do have malignant potential. Ovarian preservation should be
emphasized if possible. If normal ovary remains, the tumor should
be resected preserving ovarian tissue, especially in the case of
bilateral pathology. In this case, there was essentially no normal
ovary remaining. Oophorectomy is sufficient in FIGO stage Ia or Ib,
but in stage IIa-b, hysterectomy may be considered as well. In in-
fants, surgerymay be limited to resection of the cyst or tumor, if it is
possible to spare the ovary, as the disease tends to be less aggres-
sive in this age group. Peritoneal washings and biopsy of the
contralateral ovary should always be performed [1,2,9].
Chemotherapy is recommended only if the tumor has spread
beyond the ovaries. It is uncommon for patients to present with
advanced disease. In one study from 2002, seven patients were
identified with tumors stage II or higher. Adjuvant cisplatin-based
chemotherapy was used with all patients achieving complete
clinical remission. Radiotherapy was used in one patient with
diffuse peritoneal metastases [10]. Schneider et al., in 2005
described long-term survival and remission in four of six patients
with stages II and III JGCT following surgery and adjuvant chemo-
therapy with cisplatin-based therapy. The two patients that died
showed high proliferative activity of the malignant cells, while
survivors had lower mitotic counts. Age at diagnosis also appeared
to be prognostic, as patients younger than ten years had a more
favorable outcome [11].
Treatment of stage Ic tumors, where the tumor is confined to the
ovaries but has ruptured or the capsule has been violated at the
time of surgery, remains rather controversial. In a study of 62 pa-
tients, intraoperative rupture or violation of the tumor capsule did
not negatively impact long-term outcome or recurrence, whereas if
the tumor had ruptured preoperatively or malignant ascites was
present, these patient would likely benefit from chemotherapy [10].
If the rupture occurred intraoperatively and there were 20 mi-
toses/10HPF, then adjuvant chemotherapy should be considered
[9].
After initial surgical treatment, patients require long-term
follow-up and persistent surveillance with imaging and tumor
markers. Recurrence has been seen with stage I JGCT up to eight
years post-operatively [2].
Interestingly, a case report published in 2009 does provide
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refused bilateral oophorectomy. Two months after diagnosis of
JGCT, the patient had normal hormone levels and this persisted
over two years of follow-up [12].
Ovarian sex-cord stromal tumors (SCST), which includes JGCT as
a subtype, have also been associated with familial pleuro-
pulmonary blastoma (PPB) and the DICER1 gene mutation. The
ovarian SCST may be the initial clinical presentation of DICER1
mutations within some families, so genetic testing should be
considered in these patients, especially if they have any signs of
leprechaunism or if they develop a PPB [13,14]. These families
should also be counseled about registering with the PPB Registry at
http://www.ppbregistry.org.
This is a rare case of congenital bilateral JGCT in a patient with
no other genetic abnormalities. Initial surgical management was
left salpingo-oophorectomy with delay of right salpingo-
oophorectomy in hopes that the tumor would regress and allow
ovary-sparing surgery in the future. Especially with bilateral pa-
thology, an ovarian sparing operation should be performed when
possible. At her second operation for small bowel obstruction, the
tumor remained concerning with no residual normal ovary and
right salpingo-oophorectomy was performed. She will continue to
follow-upwith routine imaging and tumormarkers for surveillance
of late recurrence.3. Conclusion
Congenital bilateral JGCT is exceedingly rare. Ovary-sparing
surgery should be the primary goal, particularly in infants with
bilateral disease, but often this cannot be achieved. With early
diagnosis and treatment, outcomes are favorable, but long-term
follow-up is imperative to detect any late recurrences.Funding
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